摘要
目的通过分析PRAF2在肝细胞肝癌(Hepatocellular Carcinoma,HCC)中的表达水平及其与肝细胞肝癌患者临床病理特征的相关性,探究PRAF2对HCC的检测及预后判断的作用和临床意义。方法从癌症基因组图谱(The Cancer Genome Atlas,TCGA)数据库筛选出肝癌的数据及临床资料,并分析PRAF2基因表达水平与HCC患者的性别、年龄等一般资料和临床病理特征以及预后情况的相关性。结果 HCC患者癌组织中的PRAF2表达水平较癌旁组织明显上调(P<0.05),且表达水平的高低与患者的性别、年龄、肿瘤的病理学分级无关(P>0.05),与血清甲胎蛋白浓度、肿瘤的TNM分期有关(P<0.05)。PRAF2的高表达与患者总生存期及无进展生存期的缩短显著相关(P<0.05)。结论 PRAF2可作为促癌基因在HCC中高表达,有望成为HCC的早期诊断指标和预后判断指标。
Objective To investigate the prognosis value of PRAF2 expression in hepatocellular carcinoma.Methods PRAF2 expression data in the cancer genome atlas(TCGA)and its clinic pathologic features information were downloaded and screened out.Statistical assessment was performed for the correlation of the PRAF2 expression with patients’basic information,clinic pathologic features and prognosis.Results Compared with the adjacent tissue of cancer,the expression of PRAF2 was obviously up-regulated in the cancer tissue.Furthermore,the expression of PRAF2 was associated with the serum concentration of AFT and TNM stage(P<0.05).High level of PRAF2 expression indicates poor diagnosis(P<0.05).Conclusion PRAF2 is an accelerant factor in HCC,and could be used as a potential diagnostic and prognostic indicator.
作者
白黎
党钦
王锃涵
薛晨
何玉婷
BAI Li;DANG Qin;WANG Zeng-han;XUE Chen;HE Yu-ting(Department of Infection Disease,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)
出处
《医药论坛杂志》
2019年第2期1-3,共3页
Journal of Medical Forum
基金
传染病诊治国家科技重大专项(2018ZX10301201)
郑州大学第一附属医院院内青年基金(YNQN2017167)
